Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 259-653-7 | CAS number: 55466-76-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Ruthenium acetate was not mutagenic in bacterial reverse mutation assays involving five strains of Salmonella typhimurium (Thompson, 1996) and one strain of Escherichia Coli (Parnham, 1996), in the absence or presence of S9.
In a study equivalent to OECD guideline 473, and to GLP, a significant increase in the frequency of chromosome aberrations was reported in vitro in Chinese hamster lung cells, in the presence of S9 only (Durward, 1997a). Note that rodent derived cell lines with defective p53 are considered to give high rates of false positives.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 07-Nov-95 to 19-Dec-95
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Guideline study (OECD 471), to GLP, using five Salmonella strains. None of the strains utilised has the capacity to detect certain types of mutagens (e.g. oxidising or cross-linking agents). The results of this study are supplemented by those of the study reported by Parnham (1996), which utilised such a strain (E.coli).
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Remarks:
- (but no strain capable of detecting cross-linking mutagens was included)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- no
- Remarks:
- (but no strain capable of detecting cross-linking mutagens was included)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- histidine
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not applicable
- Species / strain / cell type:
- S. typhimurium TA 1538
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 from Aroclor 1254-induced male rat liver
- Test concentrations with justification for top dose:
- 0, 50, 150, 500, 1500 and 5000 ug/plate
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: water
- Justification for choice of solvent/vehicle: not stated, but well-known solvent - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- for TA100 and TA1535 -S9
- Positive control substance:
- other: N-ethyl-N'-nitro-N-nitrosoguanidine, 3 and 5 ug/plate
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- for TA1537 -S9
- Positive control substance:
- 9-aminoacridine
- Remarks:
- Migrated to IUCLID6: 80 ug/plate
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- for TA98 -S9
- Positive control substance:
- 4-nitroquinoline-N-oxide
- Remarks:
- Migrated to IUCLID6: 0.2 ug/plate
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- for TA1538 -S9
- Positive control substance:
- other: 4-Nitro-o-phenylenediamine, 5 ug/plate
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 5 for all strains +S9
- Positive control substance:
- other: 2-aminoantracene, 0.5-2 ug/plate
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in agar (plate incorporation)
DURATION
- Exposure duration: 48 hours
NUMBER OF REPLICATIONS: In triplicate
DETERMINATION OF CYTOTOXICITY
- Method: other: thinning of the background lawn
- Evaluation criteria:
- For a substance to be considered positive, it would have induced a concentration-related and statistically significant increase in mutation rate in at least one strain in the presence and/or absence of S9 in both experiments at sub-toxic concentrations; to be considered negative, the number of induced revertants at each concentration would be less than 2x the number of spontaneous revertants.
- Statistics:
- Using the methods recommended by the United Kingdom Environmental Mutagen Society (UKEMS), normally Dunnett's method of linear regression.
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1538
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
TEST-SPECIFIC CONFOUNDING FACTORS: none
RANGE-FINDING/SCREENING STUDIES: yes, preliminary toxicity study using TA100 exposed to the test material at 5000 ug/plate
COMPARISON WITH HISTORICAL CONTROL DATA: yes, within historical control range for the test laboratory
ADDITIONAL INFORMATION ON CYTOTOXICITY: no cytotoxicity- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Ruthenium acetate was not mutagenic in a guideline Ames assay with five strains of Salmonella typhimurium, when tested at up to 5 mg/plate, with and without S9.
- Executive summary:
The mutagenicity of ruthenium acetate (CAS 55466-76-7) was evaluated in an Ames test, conducted according to OECD Test Guideline 471 and to GLP. Five strains of bacteria (Salmonella typhimurium TA 1535, TA 1537, TA 1538, TA 98 and TA 100) were exposed to the test material at concentrations up to 5 mg/plate, in the presence and absence of an exogenous metabolising system (S9). No increase in the number of revertants was seen in any strain at any concentration either with or without S9. The test material was not mutagenic under the conditions of the test.
None of the strains utilised has the capacity to detect certain types of mutagens (e.g. oxidising or cross-linking agents). The results of this study are supplemented by those of the study reported by Parnham (1996), which utilised such a strain.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 22-Sep-1996 to 13-Jan-1997
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study (OECD 473) and to GLP, although no suitable positive control was included in the group tested in the absence of S9.
- Remarks:
- Note that the use of CHL cells is now not recommended due to a high incidence of false (misleading) positives (Fowler et al 2012 Reduction of misleading (“false”) positive results in mammalian cell genotoxicity assays. I. Choice of cell type, Mutation Research 742 (11-25)).
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- yes
- Remarks:
- (no suitable positive control -S9)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
- Target gene:
- Not applicable
- Species / strain / cell type:
- mammalian cell line, other: Chinese hamster lung (CHL) cell line
- Details on mammalian cell type (if applicable):
- Type and identity of media: Eagle's Minimal Essential Medium with Earle's Salts, supplemented with 10% foetal bovine serum and antibiotics
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: no data
- Periodically checked for karyotype stability: no data
- Periodically "cleansed" against high spontaneous background: no data- Additional strain / cell type characteristics:
- other: doubling time: 11 hours
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 from Aroclor 1254-induced male rat liver
- Test concentrations with justification for top dose:
- 6-hour treatment, +/-S9: 0, 313, 625, 1250, 1875, 2500 and 5000 ug/ml
24-hour treatment, -S9: 0, 39, 78, 156, 234, 323 and 625 ug/ml
48-hour treatment, -S9: 0, 10, 20, 39, 78, 156 and 313 ug/ml - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: culture medium
- Justification for choice of solvent/vehicle: test material was soluble at the required concentration. - Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- no
- Remarks:
- culture medium
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- +/-S9, 6-hour exposure
- Positive control substance:
- cyclophosphamide
- Remarks:
- inappropriate as a positive control -S9 Migrated to IUCLID6: 10 ug/ml
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- culture medium
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- -S9, 24- and 48-hour exposure
- Positive control substance:
- mitomycin C
- Remarks:
- Migrated to IUCLID6: 0.05 and 0.025 ug/ml
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 6 hours +/- S9 (also 24 and 48 hours -S9, but no chromsome aberration results presented for these exposures)
- Fixation time (start of exposure up to fixation or harvest of cells): 24 hours (after the 6-hr exposure cells were washed and left for an 18-hr recovery period in treatment free media before cell harvest)
SPINDLE INHIBITOR (cytogenetic assays): demecolcine (Colcemid, 0.1 ug/ml, 2 hours before harvest time)
STAIN (for cytogenetic assays): Gurr's Giemsa R66, 2%, 5 min
NUMBER OF REPLICATIONS: duplicate
NUMBER OF CELLS EVALUATED: 100/culture, 2 cultures per concentration (total of 200 cells/concentration)
DETERMINATION OF CYTOTOXICITY
- Method: growth inhibition estimated by counting number of cells at end of culture period on electronic cell counter (Coulter) and expressing cell count as percentage of concurrent vehicle control
OTHER EXAMINATIONS:
- Determination of polyploidy: yes
- Determination of endoreplication: no data, but presumably yes - Evaluation criteria:
- Generally, a positive result was considered to be when the proportion of cells with aberrations (including gaps) was >=10%, equivocal if 5-10% and negative if <5%; for polyploidy a 10% incidence considered positive; guidance of the United Kingdon Environmental Mutagen Society also taken into consideration, requiring expert judgement on the incidence of rare chromosomal events (exchanges)
- Statistics:
- Fisher's exact test
- Species / strain:
- mammalian cell line, other: Chinese hamster lung (CHL) cell line
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- not valid
- Species / strain:
- mammalian cell line, other: Chinese hamster lung (CHL) cell line
- Metabolic activation:
- with
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS: none
RANGE-FINDING/SCREENING STUDIES: yes, cultures exposed to test material at up to 5000 ug/ml for 6 hrs (+/-S9), or 24 or 48-hrs (-S9)
COMPARISON WITH HISTORICAL CONTROL DATA: yes, solvent controls reported to be within range for laboratory
ADDITIONAL INFORMATION ON CYTOTOXICITY: cell counts reduced and/or no metaphases at 625 ug/ml and above for 24-hour exposure (-S9), at 313 ug/ml and above for 48-hour exposure (-S9), and at 2500 ug/ml and above for 6-hour exposure (+/-S9) - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Ruthenium acetate induced a statistically significant increase in the frequency of chromosome aberrations in Chinese hamster lung cells (in vitro), in the presence of S9 only. It was therefore considered clastogenic under the conditions of the test.
- Executive summary:
The genotoxic potential of ruthenium acetate (CAS 55466-76-7) was evaluated in an in vitro chromosome aberration test (assessing structural and numerical aberrations) in Chinese hamster lung (CHL) cells using a protocol similar to that of OECD Test Guideline 473. Cultures were exposed to the test material for 6 hours (with an 18-hr recovery period) at up to 5000 ug/ml (in the presence and absence of a rat liver metabolic activation system; S9), for 24-hrs at up to 625 ug/ml (without S9), or for 48-hrs at up to 313 ug/ml (without S9). Evidence of cytotoxicity was seen at the higher doses.
In the 6 hour exposures (with S9), a high incidence of cells with chromosome aberrations was seen, which reached statistical significance at 1250, 1875 and 2500 ug/ml when compared to the solvent controls. No such increases were seen in the studies performed in the absence of S9. The test material was therefore considered clastogenic, with S9, under the conditions of the test.
Referenceopen allclose all
In the section of the study from which metaphases were scored for chromosome aberrations (6 hour exposure), the positive control substance (cyclophosphamide) was suitable only for exposure +S9; no suitable positive control for exposure -S9 (e.g. mitomycin C) was included. Since a positive result was obtained for clastogeniciy +S9, this omission has not altered the outcome of the study.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Genetic toxicity in vivo
Description of key information
No clastogenic activity was observed in the bone marrow of mice following intraperitoneal injection of ruthenium triacetate at up to 200 mg/kg bw in a guideline in vivo micronucleus test, to GLP (Durward, 1997b).
Link to relevant study records
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 16-Jan-1997 to 10-Feb-1997
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: OECD Guideline study, to GLP, with acceptable deviation (only 1000 PCEs/animal scored for micronuclei)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- yes
- Remarks:
- (only 1000 PCEs/animal scored for micronuclei)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- micronucleus assay
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd., Margate, Kent
- Age at study initiation: 5-7 weeks
- Weight at study initiation: males 24-30 g, females 21-26 g
- Assigned to test groups randomly: yes
- Fasting period before study: no data
- Housing: <=7/cage, solid floor polypropylene cages with woodflakes bedding
- Diet (e.g. ad libitum): Rat and Mouse Expanded Diet No. 1, ad libitum
- Water (e.g. ad libitum): mains water, ad libitum
- Acclimation period: >=5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-21
- Humidity (%): 47-52
- Air changes (per hr): ~15
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: From: 16-Jan-1997 To: 10-Feb-1997 - Route of administration:
- intraperitoneal
- Vehicle:
- - Vehicle(s)/solvent(s) used: physiol. saline
- Justification for choice of solvent/vehicle: no data, but well-known
- Concentration of test material in vehicle: 5, 10 and 20 mg/ml (for 50, 100 and 200 mg/kg bw doses respectively)
- Amount of vehicle (if gavage or dermal): 10 ml/kg bw
- Type and concentration of dispersant aid (if powder): not applicable
- Lot/batch no. (if required): Gibco 18Q7563
- Purity: no data - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
- freshly prepared as required as a suspension in the vehicle - Duration of treatment / exposure:
- single intraperitoneal administration
- Frequency of treatment:
- single administration
- Post exposure period:
- 24, 48 and 72 hours
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 5 mg/kg bw/day (nominal)
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Dose / conc.:
- 20 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 5/sex per dose at 24-hour timepoint;
also 5/sex at top dose at 48- and 72-hour timpoints - Control animals:
- yes, concurrent vehicle
- Positive control(s):
- cyclophosphamide
- Justification for choice of positive control(s): "known to produce micronuclei under the conditions of the test"
- Route of administration: oral
- Doses / concentrations: 50 mg/kg bw - Tissues and cell types examined:
- erythrocytes from bone marrow of femur
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION: based on range-finding study in which deaths were observed with doses of 250-2000 mg/kg bw, but not at 200 mg/kg bw or below
TREATMENT AND SAMPLING TIMES (in addition to information in specific fields): sampled at 24, 48 and 72 hours after dosing in top dose group (200 mg/kg bw) and at 24 hours in mid and low dose groups (100 and 50 mg/kg bw)
DETAILS OF SLIDE PREPARATION:
- immediately after sacrifice, 1 femur dissected/animal, aspirated with foetal calf serum
- centrifuged, resuspended and bone marrow smears prepared
- air-dried, fixed in absolute methanol, stained with May-Grunwald/Giemsa
METHOD OF ANALYSIS:
- slides coded prior to examination
- light microscopy at 1000x magnification
- incidence of micronucleated cells/1000 polychromatic erythrocytes (PCEs; blue-stained, immature cells) scored for each animal
- incidence of normochromatic erythrocytes (NCEs; pink-stained, mature cells)/1000 erythrocytes scored for each animal
- incidence of micronuclei in these NCEs scored for each animal
- ratio of PCE:NCE calculated - Evaluation criteria:
- Positive mutagenic response: statistically significant increase in number of micronucleated PCEs at any timepoint
Positive bone marrow toxicity: statistically significant decrease in group mean PCE:NCE ratio - Statistics:
- Data transformed, then analysed by 2-tailed Student's t-test; significant results confirmed using one-way analysis of variance (United Kingdom Environmental Mutagen Society (UKEMS) Sub-committee on Guidelines for Mutagenicity Testing Report, part III, 1989)
- Sex:
- male/female
- Genotoxicity:
- negative
- Remarks:
- at all doses at all timepoints
- Toxicity:
- yes
- Remarks:
- clinical signs of toxicity at top dose at all timepoints; bone marrow toxicity at top dose at 48-hour timepoint
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY
- Dose range:
- intraperitoneal: 125-2000 mg/kg bw
- oral: 1000-2000 mg/kg bw
- Solubility: administered as a suspension
- Clinical signs of toxicity in test animals:
- intraperitoneal: deaths at 250 mg/kg bw (1/2), 500 mg/kg bw (2/2), 1000 mg/kg bw (2/2) and 2000 mg/kg bw (2/2); clinical signs (including hunched posture, lethargy, decreased respiratory rate, laboured respiration, ataxia, ptosis and grey extremities) at 1000 and 2000 mg/kg bw
- oral: no deaths, no clinical signs
- Evidence of cytotoxicity in tissue analyzed: not examined in range-finding study
- Rationale for exposure: for the main study, the doses selected were the maximum tolerated dose of 200 mg/kg bw and 2 lower doses
- Harvest times: not examined in range-finding study
- High dose with and without activation: not applicable to in vivo study
RESULTS OF DEFINITIVE (MAIN) STUDY
- Clinical signs of toxicity in test animals: in top dose group (200 mg/kg bw), clinical signs of toxicity at all timepoints, including hunched posture, ptosis, dehydration, decreased respiratory rate, laboured respiration, ataxia, emaciation, lethargy, piloerection and grey extremities; deaths in 72-hour group (males 1/5, females 3/5)
- Induction of micronuclei (for Micronucleus assay): see Table 1
- Ratio of PCE/NCE (for Micronucleus assay): see Table 1
- Appropriateness of dose levels and route: appropriate; highest dose produced signs of toxicity such that higher dose levels would be expected to produce lethality; highest dose also produced some indication of toxicity in the bone marrow (i.e. a reduction in the PCE:NCE ratio at 48 hours)
- Statistical evaluation: no statistically significant increase in the number of PCE with micronuclei per 1000 PCE at any dose at any timepoint in either sex; positive control produced a highly significant increase - Conclusions:
- In a reliable in vivo study, conducted according to OECD Test Guideline 474 and to GLP, no genotoxicity was seen in the bone marrow of mice administered ruthenium acetate by intraperitoneal injection at up to 200 mg/kg bw; clinical signs of toxicity and toxicity in the bone marrow were seen at the highest dose.
- Executive summary:
Groups of 5 male and 5 female mice were administered a single intraperitoneal dose of ruthenium acetate at 50, 100 or 200 mg/kg bw and evaluated for the incidence of micronuclei in the bone marrow 24 hours after dosing. Two further groups were administered 200 mg/kg bw and evaluated 48 and 72 hours after dosing. Vehicle control groups were evaluated at each timepoint and a positive control group was orally administered cyclophosphamide at 50 mg/kg bw and evaluated at 24 hours.
Clinical signs of toxicity were seen in all groups dosed with 200 mg/kg bw and 4/10 mice died in the 72 -hour group at this dose level. Bone marrow toxicity, indicated by a decrease in the ratio of normochromatic to polychromatic erythrocytes (NCE:PCE), was seen in the 48 -hour group. There was no increase in the incidence of micronuclei at any dose at any timepoint in either sex. A clear positive response was seen in the positive control group.
In a reliable GLP study, conducted according to OECD Test Guideline 474, no genotoxicity was seen in the bone marrow of mice administered ruthenium acetate by intraperitoneal injection at up to 200 mg/kg bw; clinical signs of toxicity and toxicity in the bone marrow were seen at the highest dose.
Reference
Table 1:Results of in vivo micronucleus test with ruthenium acetate
(5 males and 5 females/group; mean ± standard deviation)
Treatment group |
Number of PCE with micronuclei per 1000 PCE |
PCE:NCE ratio |
|
|||
Group mean |
SD |
Group mean |
SD |
|||
Dose |
Sampling time (hours) |
|
||||
Vehicle control |
72 |
0.7 |
1.3 |
1.62 |
0.35 |
|
48 |
0.8 |
0.9 |
1.53 |
0.67 |
|
|
24 |
1.3 |
0.8 |
1.49 |
0.49 |
|
|
Positive control |
24 |
28.9*** |
13.1 |
1.44 |
0.5 |
|
High dose (200 mg/kg bw) |
72a |
0.3 |
0.5 |
1.25 |
0.93 |
|
48 |
0.7 |
0.9 |
0.81* |
0.52 |
|
|
24 |
0.6 |
0.7 |
1.17 |
0.31 |
|
|
Mid dose (100 mg/kg bw) |
24 |
0.5 |
0.5 |
1.55 |
0.39 |
|
Low dose (50 mg/kg bw) |
24 |
0.6 |
0.7 |
1.33 |
0.53 |
|
PCE, polychromatic erythrocyte, NCE, normochromatic erythrocyte, SD, standard deviation, *** p<0.001, * p<0.05, a data from 6 animals
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Mode of Action Analysis / Human Relevance Framework
No data identified.
Additional information
Good quality unpublished in vitro and in vivo genotoxicity studies with ruthenium (III) acetate (CAS RN 55466‑76‑7) are available.
The test substance, at up to 5 mg/plate, was not mutagenic in GLP bacterial reverse mutation assays involving five strains of Salmonella typhimurium (Thompson, 1996) and one strain of Escherichia Coli (Parnham, 1996), in the absence or presence of S9.
A significant increase in the frequency of chromosome aberrations was reported in vitro in Chinese hamster lung cells, in the presence of S9 only, in a GLP study conducted using a protocol similar to OECD Test Guideline 473 (Durward, 1997a).
However, no clastogenic activity was observed in the bone marrow of mice (10/group) following intraperitoneal injection of ruthenium triacetate at up to 200 mg/kg bw in an in vivo micronucleus test conducted according to OECD Test Guideline 474 and to GLP. Clinical signs of toxicity and toxicity in the bone marrow were seen at the highest dose (Durward, 1997b).
Justification for classification or non-classification
No evidence of genotoxic activity was seen in reliable mutagenicity assays in bacterial cells. The observation of clastogenic activity in vitro was not apparent in a reliable in vivo study assessing chromosome damage in somatic cells. No studies specifically assessing the mutagenic activity in germ cells were identified. However, due to the generally reassuring genotoxicity data on this compound, including a negative in vivo micronucleus test, classification of hexakis[mu-(acetato-O:O')]-μ3-oxo-triangulo-triruthenium acetate / ruthenium acetate for germ cell mutagenicity is not warranted, according to EU CLP criteria (EC 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.